Getting latest data loading
Home / Morning Report / Morning Report – 25th October 2022

This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.

Morning Report - 25 October 2022

Yesterday’s UK 100 Leaders Price (p) % Chg
PEARSON PLC 965.0 8.7%
PERSIMMON PLC 1,273.0 4.5%
SSE PLC 1,508.0 4.0%
BARRATT DEVELOPMENTS PLC 361.2 3.7%
BERKELEY GROUP HOLDINGS/THE 3,429.0 3.7%
Yesterday’s UK 100 Laggards Price (p) % Chg
PRUDENTIAL PLC 804.2 -9.3%
FRESNILLO PLC 698.4 -2.7%
ANTOFAGASTA PLC 1122.5 -2.2%
SCOTTISH MORTGAGE INV TR PLC 734.4 -1.8%
ANGLO AMERICAN PLC 2686.5 -1.7%

 

Major World Indices Price % Chg 1 YEAR
UK 100 INDEX 7,014 0.6% -2.9%
DOW JONES INDUS. AVG 31,500 1.3% -11.9%
DAX INDEX 12,931 1.6% -17.1%
NIKKEI 225 27,256 1.0% -4.6%
S&P/ASX 200 INDEX 6,799 0.3% -8.6%
Commodities Units Price % Chg
WTI Crude Oil (Nymex) USD/bbl. 84.70 0.14%
Brent Crude (ICE) USD/bbl. 93.22 -0.04%
Gold Spot USD/t oz. 1,649 0.0%
Copper (Comex) USd/lb. 341 -0.5%
The UK 100 is called to open +17 points this morning at 7030. 

4 hours; 8 Months

Click graph to enlarge

Markets Overview:

The UK 100 is called to open +17 points this morning at 7030.   The UK 100 is set to open slightly higher on Tuesday following further strong gains in the US wall Street saw strong advances on Monday, extending gains from last week, shrugging aside economic data which suggested the Fed’s aggressive rate raising strategy aimed at tackling soaring inflation may be slowing the economy too.  At the close the Dow Jones was up 418 points, or 1.34%, to 31,501, the S&P rose 45 points, or 1.2%, to 3,798 and the Nasdaq jumped 93 points, or 0.86%, to 10,953.

 

Company News & Broker Comments:

Company News:

AstraZeneca this morning gave an update on the MESSINA Phase III trial for Fasenra in eosinophilic esophagitis.  They said that MESSINA did not meet one of the two dual-primary endpoints, demonstrating a statistically significant improvement in histological disease remission with Fasenra, but not in dysphagia symptoms, compared to placebo

 

 

HSBC Holdings was 2.6% lower in Hong Kong, after the China-focused bank reported a decline in profit and revenue in the third quarter.  In the three months to September 30, HSBC reported pre-tax profit of $3.15 billion, down 42% from $5.40 billion a year before.

Softcat this morning reported 2022 results.  Saying they have now achieved 68 successive quarters of organic year over year income and profit growth. Also stating they will pay a special dividend this year.
THG PLC delivered their third quarter trading statement for the period ended 30 September 2022.  Q3 2022 Group revenue growth of +2.1% YoY, and +3.8% across Beauty, Nutrition and Ingenuity.  +10.2% YoY Beauty and Nutrition revenue growth in core territories with localised infrastructure, full year revenue, adjusted EBITDA and cash guidance unchanged
Whitbread this morning delivered better than expected results, statutory revenues increased by 25% versus H1 FY20 to £1,350.4m and adjusted operating profit increased by 16% to £343.2m.

Broker Comments:

No New Broker Comments

Reporting Today:

HSBC Holdings

 

Reporting Wednesday:

Softcat

 

Standard Chartered

 

Whitbread

 

In Focus Today:

 

ECB Bank Lending Survey

 

German IFO – Business Climate

 

German IFO – Current Assessment

 

German IFO – Expectations

 

US Housing Price Index

 

US S&P/Case-Shiller Home Price Indices

 

US Consumer Confidence

 

This Week's Ex-Dividends:

UK 100 companies going  ex-dividend on 27th October 2022:

 

Dechra Pharmaceuticals

 

UK 250 companies going  ex-dividend on 27th October 2022:

 

Morgan Advanced Materials

 

Foresight Solar Fund

 

City of London Investment Trust

 

Balfour Beatty

 

Bankers Investment Trust

For any help you may require placing trades or in terms of market information, put a call in to our trading floor – it’s all part of the service.


Back to Top

This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.


Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
.